Erste Asset Management GmbH Acquires 40,000 Shares of Agios Pharmaceuticals, Inc. $AGIO

Erste Asset Management GmbH raised its holdings in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 1.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,804,900 shares of the biopharmaceutical company’s stock after purchasing an additional 40,000 shares during the period. Erste Asset Management GmbH’s holdings in Agios Pharmaceuticals were worth $76,343,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in AGIO. Wellington Management Group LLP increased its stake in shares of Agios Pharmaceuticals by 485.5% in the 3rd quarter. Wellington Management Group LLP now owns 2,471,416 shares of the biopharmaceutical company’s stock valued at $99,203,000 after acquiring an additional 2,049,287 shares during the last quarter. TCG Crossover Management LLC increased its stake in shares of Agios Pharmaceuticals by 105.2% in the 3rd quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after acquiring an additional 733,038 shares during the last quarter. Capital International Investors bought a new stake in shares of Agios Pharmaceuticals in the 4th quarter valued at about $19,159,000. Balyasny Asset Management L.P. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $19,889,000. Finally, SummitTX Capital L.P. acquired a new position in shares of Agios Pharmaceuticals in the 3rd quarter valued at approximately $10,556,000.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. The Goldman Sachs Group boosted their price objective on Agios Pharmaceuticals from $28.00 to $32.00 and gave the company a “neutral” rating in a research report on Wednesday, April 1st. Citigroup boosted their price objective on Agios Pharmaceuticals from $38.00 to $46.00 and gave the company a “buy” rating in a research report on Thursday, March 5th. Truist Financial reduced their price target on Agios Pharmaceuticals from $39.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, April 30th. Wall Street Zen raised Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, March 22nd. Finally, Bank of America reduced their price target on Agios Pharmaceuticals from $41.00 to $40.00 and set a “buy” rating for the company in a research report on Friday, May 29th. Six investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.44.

Agios Pharmaceuticals Stock Performance

Shares of Agios Pharmaceuticals stock opened at $28.29 on Monday. The stock has a fifty day simple moving average of $29.63 and a 200 day simple moving average of $28.52. Agios Pharmaceuticals, Inc. has a 12-month low of $22.24 and a 12-month high of $46.00. The company has a market capitalization of $1.68 billion, a P/E ratio of -3.90 and a beta of 0.59.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported ($1.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.81) by $0.12. Agios Pharmaceuticals had a negative return on equity of 34.11% and a negative net margin of 639.84%.The business had revenue of $20.75 million during the quarter, compared to the consensus estimate of $13.30 million. The business’s revenue for the quarter was up 137.7% compared to the same quarter last year. On average, analysts predict that Agios Pharmaceuticals, Inc. will post -6.2 EPS for the current year.

Insider Buying and Selling

In related news, insider Sarah Gheuens sold 2,940 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total transaction of $102,047.40. Following the completion of the sale, the insider owned 80,277 shares in the company, valued at approximately $2,786,414.67. This represents a 3.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Tsveta Milanova sold 3,262 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $34.71, for a total value of $113,224.02. Following the sale, the insider owned 46,829 shares of the company’s stock, valued at $1,625,434.59. This trade represents a 6.51% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 12,623 shares of company stock worth $438,144. 5.40% of the stock is owned by corporate insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.